Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Journal: Science

Published: 2018-01-05

DOI: 10.1126/science.aan3706

Affiliations: 31

Authors: 48

Go to article
Institutions FC
Institute Gustave-Roussy (IGR), France 0.25
Jouy-en-Josas Centre, INRA, France 0.10
Tumour Immunology and Anti-Cancer Immunotherapy Unit, France 0.10
Cordelier Research Center (CRC), France 0.07
Équipe de Oncologie Médicale, CGFL, France 0.06
University of Paris Sud (UPSud), France 0.06
Department of Medical Oncology, IGR, France 0.06
Center of Clinical Investigations in Biotherapies of Cancer (CICBT), France 0.04
Plateforme d’Évaluation Préclinique (PFEP), IGR, France 0.02
Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), France 0.02
Fiona and Stanley Druckenmiller Center for Lung Cancer Research, MSKCC, United States of America (USA) 0.02
Molecular and Experimental Immunology and Neurogenetics (INEM), France 0.02
Paris Diderot University (Paris 7), France 0.02
Hôpital Bichat - Claude-Bernard, France 0.02
University of Paris Nord (Paris 13), France 0.02
Radiothérapie Moléculaire, France 0.02
Cell Biology Platform, IGR, France 0.01
Department of Child and Adolescent Cancer, IGR, France 0.01
Preclinical Research Platform, IGR, France 0.01
Department of Medicine, MSKCC, United States of America (USA) 0.01
Joan and Sanford I. Weill Department of Medicine, Cornell University, United States of America (USA) 0.01
Cochin Hospital, France 0.01
Centre d'études et de Recours sur les Thérapies Immunomodulatrices du Cancer (CERTIM), France 0.01
Predictive Biomarkers and Novel Therapeutic Strategies in Oncology, France 0.01
Georges Pompidou European Hospital (HEGP), France 0
Karolinska University Hospital, Sweden 0

Return